Search clinical trials for: IFN-β-1a (Rebif®)

Total 419 results

Waukesha Memorial Hospital
The Cleveland Clinic

Completed

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Relapsing-Remitting Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany

Completed

Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

Multiple Sclerosis

Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting
Brigham and Women's Hospital
EMD Serono

Withdrawn

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
Biogen

Withdrawn

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (Frequency)

Relapsing Multiple Sclerosis
Teva Neuroscience, Inc.

Completed

Therapy Optimization in Multiple Sclerosis (MS) (TOP MS)

Multiple Sclerosis

United States
EMD Serono
Merck Serono International SA

Completed

Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

Multiple Sclerosis, Relapsing-remitting
Merck KGaA, Darmstadt, Germany

Completed

Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Merck KGaA, Darmstadt, Germany
Merck spol.s.r.o., Czech Republic

Completed

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (SKORE)

Multiple Sclerosis, Relapsing-Remitting

Czech Republic
Biogen

Completed

Plegridy Observational Program (POP)

Relapsing Forms of Multiple Sclerosis

United States, Italy, Switzerland, Canada, Australia, Germany, Spain, France, Portugal, Netherlands, United Kingdom, Denmark, Austria, Ireland
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

Multiple Sclerosis

Germany
Centre Hospitalier Universitaire Vaudois
BioPartners GmbH

Completed

Phase I BP Interferon (IFN) Beta-004

Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (REMAIN)

Multiple Sclerosis, Relapsing-Remitting
Neurognostics

Terminated

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

United States
EMD Serono
Merck Serono International SA

Completed

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

Multiple Sclerosis, Relapsing-Remitting
EMD Serono
Merck Serono International SA

Completed

Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

Ulcerative Colitis

Sweden, Germany, Netherlands, Israel, Singapore, Switzerland, United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (RETURN)

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany

Completed

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (RELIEF)

Multiple Sclerosis, Relapsing-Remitting

Germany
Biogen

Completed

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Multiple Sclerosis

United States
Johns Hopkins University
Biogen

Withdrawn

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Cyclo Therapeutics, Inc.

Active, not recruiting

Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C

Niemann-Pick Disease, Type C1

United States
Sanofi

Completed

A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis (TENERE)

Multiple Sclerosis

Hungary, Belgium, Germany, Italy, Greece, France, Poland, Spain, Canada, Switzerland, Czech Republic, Tunisia, United Kingdom
EMD Serono

Terminated

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (RESOunD)

Multiple Sclerosis

United States
PD Dr. Marcus Müller
BfARM, Bonn; DZNE, Bonn

Unknown

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Relapsing-remitting Multiple Sclerosis

Germany
Celgene

Completed

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (SUNBEAM)

Multiple Sclerosis

United States, Spain, Czechia, Russian Federation, Portugal, Serbia, United Kingdom, New Zealand, Belarus, Bulgaria, Poland, Romania, Estonia, Germany, Sweden, Ukraine, Hungary, Croatia, Georgia, Bosnia and Herzegovina, Latvia, Li... and more
Merck KGaA, Darmstadt, Germany

Completed

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (REFLEXION)

Multiple Sclerosis | Clinically Isolated Syndrome

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Estonia, Germany, Latvia, Poland, Romania, Argentina, Finland, Israel, Greece, Czech Republic, Slovakia, Austria, Belgium, Canada, Lebanon, Morocco, Portugal, Serbia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) (BRAVO)

Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Biocad

Completed

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation
EMD Serono

Completed

Rebif New Formulation (RNF) Quality of Life (QOL) Study (RebiQoL)

Relapsing Multiple Sclerosis

United States
Biogen
AbbVie

Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))

Relapsing-Remitting Multiple Sclerosis

Sweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
EMD Serono
Pfizer

Completed

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

United States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease (REAL)

Alzheimer's Disease

Italy
German University in Cairo

Recruiting

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Multiple Sclerosis

Egypt
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO)

Relapsing Remitting Multiple Sclerosis

Portugal
Aaron Boster
Pfizer; EMD Serono

Completed

Combination Therapy Using Cellcept and Rebif in RRMS

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany

Completed

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device (RebiQoL)

Multiple Sclerosis | Relapsing-Remitting

Sweden, Germany
EMD Serono

Completed

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) (REPLAY)

Multiple Sclerosis

Italy, Russian Federation, United States, Argentina, Venezuela, Canada, Tunisia, France
Genzyme, a Sanofi Company
Bayer

Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One (CARE-MS I)

Multiple Sclerosis, Relapsing-Remitting

Australia, France, United States, Germany, Canada, United Kingdom, Russian Federation, Argentina, Brazil, Croatia, Poland, Serbia, Sweden, Ukraine, Czech Republic, Mexico
Merck KGaA, Darmstadt, Germany
Merck Serono Middle East FZ LLC

Completed

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Relapsing Multiple Sclerosis (RMS)

Bulgaria, Poland, Argentina, Hungary, Korea, Republic of, Saudi Arabia, Egypt, Algeria, Bahrain, Iran, Islamic Republic of, Kuwait, Lebanon, Morocco
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaborators

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting

Greece
Beingmate Baby & Child Food Co Ltd .
Shanghai Jiao Tong University School of Medicine

Unknown

Influence of Improved Formula on Fatty Acids and Mineral Metabolism in Infants

Healthy

China
Sanofi

Completed

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, Italy, Spain, United Kingdom, Austria
Biogen

Withdrawn

Brimonidine Tartrate for the Treatment of Injection Related Erythema (BRITE)

Relapsing-Remitting Multiple Sclerosis (RRMS)
Miltenyi Biomedicine GmbH
City of Hope Comprehensive Cancer Center

Not yet recruiting

M-2018-334 in Hematological Malignancies (HAPLO2022)

Hematological Malignancies

Search clinical trials for: IFN-β-1a (Rebif®)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations